{"id":53764,"date":"2023-02-08T23:02:12","date_gmt":"2023-02-08T22:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/"},"modified":"2023-02-08T23:02:12","modified_gmt":"2023-02-08T22:02:12","slug":"toragen-inc-announces-appointment-of-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/","title":{"rendered":"Toragen, Inc. Announces Appointment of Chief Scientific Officer"},"content":{"rendered":"
\n

\nToragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d)<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.\n<\/p>\n

<\/a><\/p>\n

\nDr. Lumpkin joined Toragen in late 2018 as a consultant and became a fulltime employee in mid-2022. Sandra Coufal, MD, Toragen\u2019s CEO said, \u201cWe are thrilled to have Rick as our Chief Scientific Officer as he brings over 30 years of significant experience in early-stage biotechnology companies and synthetic chemistry. Rick has already made important discoveries at Toragen and has directed the foundational science to swiftly proceed to the clinic.\u201d\n<\/p>\n

\nPrior to Toragen, Dr. Lumpkin served as a founding employee at Global Blood Therapeutics, Portola Pharmaceuticals and Millennium Pharmaceuticals. Additionally, Dr. Lumpkin brings experience from COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.\n<\/p>\n

\nAbout Toragen<\/b>\n<\/p>\n

\nToragen, Inc. is targeting the root cause of virally induced cancers. https:\/\/toragen.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nToragen, Inc.
\n
Cheryl Collett
\n
CFO
\n
ccollett@toragen.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53764","6":"format-standard","7":"category-industry"},"yoast_head":"\nToragen, Inc. Announces Appointment of Chief Scientific Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Toragen, Inc. Announces Appointment of Chief Scientific Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-08T22:02:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230208005920\/en\/1709173\/21\/Toragen_Wordmark_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Toragen, Inc. Announces Appointment of Chief Scientific Officer\",\"datePublished\":\"2023-02-08T22:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/\"},\"wordCount\":194,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005920\\\/en\\\/1709173\\\/21\\\/Toragen_Wordmark_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/\",\"name\":\"Toragen, Inc. Announces Appointment of Chief Scientific Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005920\\\/en\\\/1709173\\\/21\\\/Toragen_Wordmark_Logo.jpg\",\"datePublished\":\"2023-02-08T22:02:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005920\\\/en\\\/1709173\\\/21\\\/Toragen_Wordmark_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005920\\\/en\\\/1709173\\\/21\\\/Toragen_Wordmark_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/toragen-inc-announces-appointment-of-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Toragen, Inc. Announces Appointment of Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Toragen, Inc. Announces Appointment of Chief Scientific Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/","og_locale":"en_US","og_type":"article","og_title":"Toragen, Inc. Announces Appointment of Chief Scientific Officer - Pharma Trend","og_description":"Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d) SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (\u201cHPV\u201d), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-08T22:02:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230208005920\/en\/1709173\/21\/Toragen_Wordmark_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Toragen, Inc. Announces Appointment of Chief Scientific Officer","datePublished":"2023-02-08T22:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/"},"wordCount":194,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230208005920\/en\/1709173\/21\/Toragen_Wordmark_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/","url":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/","name":"Toragen, Inc. Announces Appointment of Chief Scientific Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230208005920\/en\/1709173\/21\/Toragen_Wordmark_Logo.jpg","datePublished":"2023-02-08T22:02:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230208005920\/en\/1709173\/21\/Toragen_Wordmark_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230208005920\/en\/1709173\/21\/Toragen_Wordmark_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/toragen-inc-announces-appointment-of-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Toragen, Inc. Announces Appointment of Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53764"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53764\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}